We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 2

1.
Figure 2

Figure 2. From: Biomarkers of response and resistance to antiangiogenic therapy.

Modes of vessel recruitment to tumors that might be involved in tumor escape from antiangiogenic therapy. Abbreviations: bFGF, basic fibroblast growth factor; BMC, bone marrow cell; IL-6, interleukin 6; SDF1α, stromal-cell-derived factor 1α. Adapted with permission from Nature Publishing Group © Carmeliet, P. and Jain, R. K. Nature 407, 249–257 (2000).

Rakesh K. Jain, et al. Nat Rev Clin Oncol. ;6(6):327-338.
2.
Figure 1

Figure 1. From: Biomarkers of response and resistance to antiangiogenic therapy.

Candidate biomarkers of response and resistance to antiangiogenic therapy. At baseline, the genotype of VEGF and/or IL-8 might associate with outcome of bevacizumab with chemotherapy. Randomized trials will establish if the biomarkers are predictive or prognostic. Among dynamic biomarkers, the extent of hypertension, decrease in Ktrans (in patients with glioblastoma or hepatocellular carcinoma), increase in small (cerebral) blood vessel volume (glioblastoma) and/or increase in circulating collagen IV (glioblastoma) might be predictive of outcome of antiangiogenic therapy. Finally, molecular pathways such as SDF1α (in glioblastoma, hepatocellular carcinoma or renal-cell carcinoma), IL-6 (in hepatocellular carcinoma or renal-cell carcinoma) or bFGF (glioblastoma), and CPCs (in hepatocellular carcinoma) might be associated with resistance to antiangiogenic therapy. Abbreviations: bFGF, basic fibroblast growth factor, CBV, cerebral blood volume; CPC, circulating progenitor cell; IL, interleukin; LDH, lactate dehydrogenase; SDF1α, stromal-cell-derived factor 1α; sICAM1, soluble intracellular adhesion molecule 1.

Rakesh K. Jain, et al. Nat Rev Clin Oncol. ;6(6):327-338.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk